secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0000950170-24-098485
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio appoints Dr. Lloyd Klickstein to its Board, effective August 19, 2024
--------------------------------------------------------------------------------

- Dr. Michael Kauffman resigned from Board and Nominating Committee effective Aug 19, 2024; no disagreement cited.
- Dr. Lloyd Klickstein, M.D., Ph.D., appointed as Class III director and to Nominating Committee; term through 2027 annual meeting.
- Klickstein received an option for 70,200 shares, vesting over 36 months, plus standard non-employee director compensation.
- Klickstein previously served as Adicet's Chief Innovation Officer and has leadership experience at Novartis and Eli Lilly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/0000950170-24-098485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/acet-20240815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-098485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer